Insider · CIK 0001532513

Repella Robert

Reports to the SEC for 2 companies · ROCKVILLE, MD

sec.gov

Transactions

Companies

Filings

CIK

0001532513

Forms 4 and 5

Insider transactions

19 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2019-05-21	Biohaven Pharmaceutical Holding Co Ltd.Stock Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2018-09-07	Biohaven Pharmaceutical Holding Co Ltd.Stock Option (right to buy)A Award	Director	AAward	+36K sh	—	—	36,000
2013-11-21	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+23K sh	$5.90	+$136K	44,530
2013-11-21	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+34.6K sh	$3.12	+$108K	79,100
2013-11-21	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−64.1K sh	$12.12	−$777K	15,000
2013-11-21	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	−23K sh	—	—	166,445
2013-11-21	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	−34.6K sh	—	—	21,680
2013-11-20	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+40.5K sh	$5.90	+$239K	62,005
2013-11-20	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−40.5K sh	$11.89	−$482K	21,490
2013-11-20	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	−40.5K sh	—	—	189,485
2013-11-19	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−2,885 sh	$12.07	−$34.8K	21,490
2013-07-29	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+9,375 sh	—	—	24,375
2013-07-29	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitM Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	−9,375 sh	—	—	9,375
2013-02-14	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+15K sh	—	—	15,000
2013-02-14	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitM Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	−15K sh	—	—	45,000
2012-12-07	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP & Chief Commercial Officer	AAward	+56.3K sh	—	—	56,250
2012-12-07	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitA Award	SVP & Chief Commercial Officer	AAward	+18.8K sh	—	—	18,750
2011-10-24	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP & Chief Commercial Officer	AAward	+230K sh	—	—	230,000
2011-10-24	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitsA Award	SVP & Chief Commercial Officer	AAward	+60K sh	—	—	60,000

Recent filings

Accepted (ET)
May 234
Repella Robert0001209191-19-032470
SEC(opens sec.gov)
Sep 114
Repella Robert0001209191-18-050473
SEC(opens sec.gov)
Nov 214
Vanda Pharmaceuticals Inc.0001209191-13-053649
SEC(opens sec.gov)
Jul 314
Vanda Pharmaceuticals Inc.0001209191-13-038505
SEC(opens sec.gov)
Feb 194
Repella Robert0001209191-13-009931
SEC(opens sec.gov)
Dec 114
Repella Robert0001209191-12-056936
SEC(opens sec.gov)
Oct 254
Repella Robert0001209191-11-052629
SEC(opens sec.gov)

Companies

Address

9605 MEDICAL CENTER DRIVE, SUITE 300

ROCKVILLE, MD, 20850